Canada: NACI recommends that AstraZeneca coronavirus vaccine should not be used in adults under 55 years of age

NACI recommends that AstraZeneca COVID-19 vaccine should not be used in adults under 55 years of age at this time while the safety signal of Vaccine-Induced Prothrombotic Immune Thrombocytopenia (VIPIT) following vaccination with AstraZeneca COVID-19 vaccine is investigated further.  More...

Joint Statement on the WHO-Convened COVID-19 Origins Study signed by 14 countries

The text of the following statement was released by the Governments of the United States of America, Australia, Canada, Czechia, Denmark, Estonia, Israel, Japan, Latvia, Lithuania, Norway, the Republic of Korea, Slovenia, and the United Kingdom.

 More...

Sudden rise in COVID-19 case fatality among young and middle-aged adults in the south of Brazil after identification of the novel B.1.1.28.1 (P.1) SARS-CoV-2 coronavirus strain

Individuals between 20 and 29 years of age whose diagnosis was made in February 2021 had an over 3-fold higher risk of death compared to those diagnosed in January 2021, while those aged 30-39, 40-49, 50-59 years experienced 93%, 110%, and 80% increases in risk of death, respectively.  More...

U.S. halts distribution of Eli Lilly’s coronavirus antibody treatment bamlanivimab as a monotherapy

The U.S. government has halted distribution of Eli Lilly’s COVID-19 antibody treatment bamlanivimab (LY-CoV555) as a monotherapy just four months after it received FDA emergency use authorization, citing a sustained increase in variants of SARS-CoV-2 that are resistant to the monotherapy.  More...